Press-release for stocks for SNYNF

symbols : SNYNF

save search

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M

Health Technology

| -3.7% | O: 2.02% H: 1.41% C: 0.92%
vaccine trials

XORTX Announces New Clinical Advisory Board Member - March 27, 2024
Published: 2024-03-27 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
XRTX | $3.5 -3.05% -3.14% 12K

Mining, Quarrying, and Oil and ...

| 1.84% | O: 0.0% H: 0.0% C: -5.79%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%

XORTX Announces New Clinical Advisory Board Member
Published: 2024-03-27 (Crawled : 09:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
XRTX | $3.5 -3.05% -3.14% 12K

Mining, Quarrying, and Oil and ...

| 1.84% | O: 0.0% H: 0.0% C: -5.79%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
Published: 2024-03-26 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
TGAN | $4.805 0.1% 0.1% 380K

Manufacturing

| -2.04% | O: 0.2% H: 0.0% C: -0.2%
FREE | $4.835 0.1% 0.1% 220K

Consumer Non-Durables

| 0.0% | O: 0.0% H: 0.21% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%
INBX | $34.36 -0.26% -0.26% 220K

Health Technology

| -1.31% | O: 0.29% H: 0.23% C: -0.06%
HMST | $12.64 3.44% 3.32% 54K

Finance

| -19.41% | O: 0.26% H: 0.07% C: -0.85%
EVBG | $34.875 -0.01% -0.01% 1.2M

Technology Services

| 0.23% | O: 0.09% H: 0.03% C: -0.03%

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| -3.11% | O: 0.49% H: 0.84% C: -0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -6.6% | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study

Biond Biologics Announces Presentation of BND-35, a Novel Anti-ILT3 Antibody for Remodeling the Tumor Microenvironment, at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-03-26 (Crawled : 20:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.72% | O: 1.93% H: 0.0% C: 0.0%
bnd-35 antibody association presentation cancer tumor research meeting

Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie, AstraZeneca, Merck & Co., Novartis, Pfizer and more
Published: 2024-03-26 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -6.86% | O: 0.3% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%
companies merck disorders global market

Umicore - Notice of ordinary and special shareholders’ meetings
Published: 2024-03-26 (Crawled : 08:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.72% | O: 1.93% H: 0.0% C: 0.0%

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Published: 2024-03-25 (Crawled : 00:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
million

FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
fda cancer blood therapy

Regeneron Hit With Two CRLs, J&J’s PAH Treatment Approved
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
PRGO | News | $30.8 2.87% -1.14% 1.2M

Health Technology

| -4.09% | O: 0.35% H: 0.35% C: -1.34%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -6.82% | O: 0.04% H: 0.0% C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M

Health Technology

| -3.77% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
approved treatment

Biopharma Layoff Tracker 2024: Theratechnologies, GSK, NextCure and More Cut Staff
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
RLYB | News | $1.75 4.79% 4.57% 310K

| 6.87% | O: 2.5% H: 1.22% C: -8.54%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -6.82% | O: 0.04% H: 0.0% C: 0.0%
VXRT | News | $0.7652 -9.15% -10.08% 1.9M

Health Technology

| -30.95% | O: 1.59% H: 0.0% C: -3.91%
TXMD | News | $1.86 -1.59% -1.61% 10K

Health Technology

| -17.47% | O: 2.18% H: 0.0% C: -2.14%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
PTCT | News S | $25.32 2.55% 2.49% 3.9M

Health Technology

| -13.51% | O: -0.31% H: 2.62% C: -0.48%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| 47.78% | O: 0.71% H: 0.83% C: -3.47%
MOR | News | $17.96 -0.5% -0.5% 180K

Health Technology

| -0.72% | O: 0.0% H: 0.22% C: -0.17%
GLPG | News | $29.095 0.64% 0.64% 87K

Health Technology

| -10.81% | O: -0.09% H: 0.31% C: -0.15%
AMRN | News | $0.88 0.94% 0.93% 1M

Health Technology

| 8.06% | O: 1.2% H: 0.99% C: -3.0%
GOOGL | News S | $154.08 -1.24% -1.25% 32M

Technology Services

| 3.01% | O: -0.55% H: 0.29% C: 0.09%
GOOG | News S | $155.7 -1.12% -1.13% 20M

Technology Services

| 3.39% | O: -0.54% H: 0.34% C: 0.13%
OCX | News J | $2.495 -2.54% -2.61% 50K

Health Technology

| -15.36% | O: -2.08% H: 0.73% C: 0.73%
biopharma

Dyne Therapeutics Announces CEO Transition
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
DYN | $23.89 1.02% 1.0% 970K

Health Technology

| -12.78% | O: -13.24% H: 11.02% C: 6.37%
BIIB | $194.39 2.03% 1.99% 1.6M

Health Technology

| -10.52% | O: -0.15% H: 0.23% C: -0.5%
ceo therapeutics

Regeneron Provides Update on Biologics License Application for Odronextamab
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K

Health Technology

| -6.83% | O: -1.37% H: 1.15% C: 0.74%
license update application

Italfarmaco’s Duvyzat, Idorsia’s Tryvio Earn FDA Nods for DMD, Hypertension
Published: 2024-03-22 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -2.65% | O: -1.58% H: 0.0% C: 0.0%
PRGO | News | $30.8 2.87% -1.14% 1.2M

Health Technology

| -4.88% | O: 0.35% H: 0.99% C: -1.17%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -6.81% | O: 0.02% H: 0.0% C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M

Health Technology

| -5.0% | O: -0.43% H: 0.41% C: -0.85%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.11% | O: 1.47% H: 0.23% C: -0.19%
fda hypertension

Biopharma Layoff Tracker 2024: GSK, NextCure, Catalent and More Cut Staff
Published: 2024-03-22 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology